Last reviewed · How we verify
ARQ-151 vehicle cream
ARQ-151 is a topical phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory cytokine production in skin.
ARQ-151 is a topical phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory cytokine production in skin. Used for Atopic dermatitis, Plaque psoriasis.
At a glance
| Generic name | ARQ-151 vehicle cream |
|---|---|
| Sponsor | Arcutis Biotherapeutics, Inc. |
| Drug class | Phosphodiesterase 4 (PDE4) inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
PDE4 inhibition increases intracellular cAMP levels in immune and inflammatory cells, suppressing the release of pro-inflammatory mediators such as TNF-α, IL-23, and IL-17. This mechanism reduces skin inflammation and is designed for topical treatment of inflammatory skin conditions. The vehicle cream formulation allows localized delivery to affected skin areas.
Approved indications
- Atopic dermatitis
- Plaque psoriasis
Common side effects
- Application site irritation
- Application site erythema
- Pruritus
Key clinical trials
- Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED) (PHASE3)
- Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (PHASE3)
- Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II) (PHASE3)
- Safety and Efficacy of ARQ-151 Cream in Adolescents and Adults With Atopic Dermatitis (PHASE2)
- Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis (PHASE3)
- Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis (PHASE3)
- The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis (PHASE2)
- Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARQ-151 vehicle cream CI brief — competitive landscape report
- ARQ-151 vehicle cream updates RSS · CI watch RSS
- Arcutis Biotherapeutics, Inc. portfolio CI